World's Best Scientists 2026 revealed!
Dongsheng Tu

Dongsheng Tu

D-Index & Metrics

Medicine

D-Index
86
Citations
51769
World Ranking
13846
National Ranking
570

Dongsheng Tu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Dongsheng Tu sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 391 publications — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Dongsheng Tu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Dongsheng Tu sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Dongsheng Tu is affiliated with Queen's University in Canada and has a body of research primarily focused on medicine, with a significant emphasis on oncology. Their work spans a range of subfields including oncology, statistics and probability, cancer research, pulmonary and respiratory medicine, and economics and econometrics.

The scientist's research topics cover detailed studies and treatments in colorectal cancer, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, and statistical methods in clinical trials. Other notable areas include genetic factors in colorectal cancer and ovarian cancer diagnosis and treatment.

Frequent co-authors of Dongsheng Tu include Derek J. Jonker, Jonathan M. Loree, Christopher J. O'Callaghan, Hagen F. Kennecke, and Chris J. O'Callaghan.

Important publication venues for their research include the Journal of Clinical Oncology, Statistics in Medicine, Clinical Cancer Research, European Journal of Cancer, and Pain.

Significant recent papers by Dongsheng Tu are:

  • Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer, 2020, JAMA Oncology
  • Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial, 2021, The Lancet Oncology
  • Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer, 2024, New England Journal of Medicine
  • Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies, 2022, Nature Communications
  • The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma, 2022, Nature Communications

Best Publications

  • Erlotinib in previously treated non-small-cell lung cancer.

    Frances A. Shepherd;José Rodrigues Pereira;Tudor Ciuleanu;Eng Huat Tan

  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

    Christos S Karapetis;Shirin Khambata-Ford;Derek J Jonker;Chris J O'Callaghan

  • The jackknife and bootstrap

    Jun Shao;Dongsheng Tu

  • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

    Christine M. Ribic;Daniel J. Sargent;Malcolm J. Moore;Malcolm J. Moore;Stephen N. Thibodeau

  • Cetuximab for the Treatment of Colorectal Cancer

    Derek J Jonker;Chris J O'Callaghan;Christos S Karapetis;John R Zalcberg

  • Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Morphine, Gabapentin, or Their Combination for Neuropathic Pain

    Ian Gilron;Joan M. Bailey;Dongsheng Tu;Ronald R. Holden

  • Exemestane for Breast-Cancer Prevention in Postmenopausal Women

    Paul E. Goss;James N. Ingle;José E. Alés-Martínez;Angela M. Cheung

  • Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

    M. N. Levine;V. H. Bramwell;K. I. Pritchard;B. D. Norris

  • Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

    Wendy De Roock;Derek J Jonker;Federica Di Nicolantonio;Andrea Sartore-Bianchi

  • Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.

    Astec;P Blake;Ann Marie Swart

  • HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

    Kathleen I. Pritchard;Lois E. Shepherd;Frances P. O'Malley;Irene L. Andrulis

  • Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma

    Aileen M. Davis;Aileen M. Davis;Brian O'Sullivan;Robert Turcotte;Robert Bell;Robert Bell

  • Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

    Paul E. Goss;James N. Ingle;Kathleen I. Pritchard;Nicholas J. Robert

  • Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

    Emmanuel Mitry;Anthony L.A. Fields;Harry Bleiberg;Roberto Labianca

  • Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix

    R. Pearcey;M. Brundage;P. Drouin;J. Jeffrey

  • Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial

    Ian Gilron;Ian Gilron;Joan M Bailey;Joan M Bailey;Dongsheng Tu;Ronald R Holden

  • Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Malcolm J. Moore;J. Hamm;J. Dancey;P. D. Eisenberg

  • Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

    Andrea Bezjak;Dongsheng Tu;Lesley Seymour;Gary Clark

Frequent Co-Authors

Lesley Seymour
Lesley Seymour Queen's University
Kathleen I. Pritchard
Kathleen I. Pritchard University of Toronto
Paul E. Goss
Paul E. Goss Harvard University
John R. Zalcberg
John R. Zalcberg Monash University
Malcolm J. Moore
Malcolm J. Moore Princess Margaret Cancer Centre
James N. Ingle
James N. Ingle Mayo Clinic
John Simes
John Simes University of Sydney
Elizabeth A. Eisenhauer
Elizabeth A. Eisenhauer Queen's University
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but not ready to commit to a full medical degree, there are flexible online pathways to consider. The demand for nurses continues to grow, and online nursing programs provide multiple entry points for students with diverse backgrounds.

For those seeking advanced qualifications, online nursing doctoral programs can help you reach leadership or teaching roles without relocating. If you're a registered nurse looking to enhance your credentials, exploring the rn to bsn online cost can help you find affordable options and accelerate your career.

Non-nurses interested in fast-tracking their education can research direct entry msn programs for non nurses online for efficient routes into advanced nursing roles. For those concerned about admissions, there are also easy nursing programs to get into that provide accessible opportunities.

Exploring these related online degrees and career pathways offers flexibility, affordability, and the chance to enter rewarding healthcare careers—often from the comfort of your home.

Best Scientists Citing Dongsheng Tu

Trending Scientists

Recently Published Articles